USA flag logo/image

An Official Website of the United States Government

Sphingosine Kinase Inhibitors as Anti-Arthritis Agents

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75980
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
AR052261
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
APOGEE BIOTECHNOLOGY CORPORATION
1214 Research Blvd Suite 2014 HUMMELSTOWN, PA 17036-9196
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2008
Title: Sphingosine Kinase Inhibitors as Anti-Arthritis Agents
Agency: HHS
Contract: 2R44AR052261-02A1
Award Amount: $996,642.00
 

Abstract:

DESCRIPTION (provided by applicant): Sphingolipids are being increasingly recognized as key mediators of inflammatory cascades of critical importance in multiple diseases, including rheumatoid arthritis and osteoarthritis. Most importantly, sphingosine 1-phosphate produced by sphingosine kinase (SK) mediates the effects of tumor necrosis factor-1 and interleukin-12, pro-inflammatory cytokines that are central to pathologic processes in these diseases. Because of this pivotal role of SK in regulating inf lammation, we are developing SK inhibitors to be used as drugs to treat arthritis. In Phase I of this project, we demonstrated that our proprietary SK inhibitors block signaling pathways induced by inflammatory cytokines in cell culture. Importantly, we fu rther demonstrated that oral administration of the SK inhibitors attenuates the development of collagen-induced arthritis in mice and adjuvant-induced arthritis in rats. These therapeutic effects of the SK inhibitors are manifested without toxicity to the animals. These studies provide the first proof-of-principle demonstration that SK inhibitors are likely to be effective in the treatment of arthritis. In Phase II of this project, we will more thoroughly evaluate the therapeutic efficacy of an optimized fo rmulation of the leading SK inhibitor in multiple models of rheumatoid arthritis and osteoarthritis. Additionally, we will determine the optimal schedule for treatment of the animals, and examine the therapeutic effects of combining the SK inhibitor with e stablished anti-arthritis drugs. Both of these activities will be important for subsequent translation to clinical trials. The following Specific Aims will be addressed: 1. To confirm the therapeutic activity of ABC294640 in three experimental models of rh eumatoid arthritis. 2. To determine the therapeutic activity of ABC294640 in two experimental models of osteoarthritis. 3. To determine the therapeutic activity of ABC294640 in combination with established anti- arthritis drugs. 4. To determine the pharmac okinetics and the optimal treatment schedule for ABC294640. Upon completion of these experiments, we will be ready to begin clinical testing of a new chemical entity directed toward a new molecular target critical for progression of arthritis. Therefore, t hese studies provide a focused approach for moving a novel inhibitor of SK into clinical trials for the treatment of these debilitating diseases. PUBLIC HEALTH RELEVANCE Sphingosine kinase (SK) is a critical enzyme involved in the pathogenesis of arthritis . In this project, we have developed inhibitors of SK and shown them to have therapeutic efficacy in arthritis models. Continued development of these compounds may provide important new drugs for the treatment of arthritis.

Principal Investigator:

Business Contact:


cdsmith@apogee-biotech.com
Small Business Information at Submission:

APOGEE BIOTECHNOLOGY CORPORATION
1214 Research Blvd Suite 1016 Hummelstown, PA 17036

EIN/Tax ID: 251901043
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No